CJC 1295 (with DAC) 5MG

£38.00

CJC-1295 with DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) chemically modified with a Drug Affinity Complex (DAC) to enable extended persistence in experimental systems.

Batch tested Purity: ≥ 99 % (HPLC / SEC, typical)
CAS Number: 863288-34-0
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Guaranteed Safe Checkout

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.

Reconstitution

Use bacteriostatic water. Add solvent slowly along vial wall. Do not shake gently swirl.

Cold Chain

Store lyophilised at 2–8°C. Once reconstituted, keep at 2–8°C and use within 28 days.

Certificate of Analysis

CoA available on request for each batch. HPLC and MS data provided.

Description

Batch HPLC tested at 98.5%+ purity
Store frozen long term or in fridge when ready to be used
Sold for research purposes only
Contact us for Wholesale Orders

CJC-1295 with DAC

Synonyms / Designations: CJC-1295-DAC, DAC:GRF
CAS Number: 863288-34-0
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol
Peptide Classification: Synthetic growth hormone–releasing hormone (GHRH 1–29) analogue conjugated with Drug Affinity Complex (DAC)
Purity: ≥ 99 % (HPLC, typical)
Appearance: White to off-white lyophilised powder
Storage: Desiccated, protected from light, stored at –20 °C
Solubility: Soluble in sterile water and buffered aqueous solutions

Description & Mechanism

CJC-1295 with DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) that has been chemically modified through conjugation with a Drug Affinity Complex (DAC). The DAC moiety consists of a reactive linker designed to form a covalent association with circulating serum albumin, resulting in prolonged systemic persistence of the peptide in experimental systems. This bioconjugation alters pharmacokinetic behaviour while preserving the core peptide sequence responsible for receptor interaction.

In biochemical and cellular research models, CJC-1295 with DAC interacts with the GHRH receptor expressed on pituitary-derived cells, initiating intracellular signalling cascades associated with growth hormone secretion. Preclinical and clinical research studies have examined receptor activation dynamics, signalling duration, and downstream endocrine pathway engagement under extended exposure conditions. Observed molecular and physiological responses are dependent on experimental design, dosing paradigm, and model system, and are used to investigate prolonged GHRH receptor signalling rather than defined biological or physiological outcomes.

Applications in Research

As a molecular probe to study GHRH receptor binding and activation dynamics.
Investigation of growth hormone axis signalling and endocrine feedback mechanisms.
In cellular assays examining downstream transcriptional and signalling responses.
In preclinical or clinical research models assessing extended-duration peptide–receptor interaction resulting from albumin binding

Handling, Reconstitution & Stability

Weigh under dry conditions; peptide is hygroscopic.
Reconstitute in sterile water or appropriate buffered aqueous solution depending on assay requirements.
Avoid vigorous agitation during dissolution due to peptide–DAC conjugation.
Filter sterilize if required (e.g. 0.22 µm) immediately prior to use.
Aliquot and store reconstituted solutions at –20 °C (or lower) to avoid repeated freeze–thaw cycles.
Inspect solutions for precipitation or changes in clarity before use in sensitive assays.

Precautions & Notes

Experimental behaviour of CJC-1295 with DAC is influenced by albumin binding, concentration, and dosing schedule.
Buffer composition, pH, and ionic strength may affect peptide stability and assay performance.
This compound was previously evaluated in clinical research settings; development was discontinued following precautionary termination unrelated to demonstrated peptide-specific toxicity.
CJC-1295 has been reported in anti-doping and forensic literature; such classifications are unrelated to laboratory research use.
Intended strictly for laboratory research use; not for human or veterinary application.

References

Teichman S.L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
https://pubmed.ncbi.nlm.nih.gov/16352683/

Ionescu M., Frohman L.A. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting growth hormone–releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 2006.
https://pubmed.ncbi.nlm.nih.gov/17018654/

Alba M. et al. Once-daily administration of CJC-1295, a long-acting growth hormone–releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology – Endocrinology and Metabolism, 2006.
https://pubmed.ncbi.nlm.nih.gov/16670156/

Keywords: CJC-1295 with DAC, DAC:GRF, GHRH Analogue